Abstract
Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.
Keywords: Infectious diarrhoea, MMX, non-absorbable antibiotics, rifamycin SV, rifaximin.
Anti-Infective Agents
Title:Efficacy of the Treatment of Infectious Diarrhoea with Non-Absorbable Rifamycin SV Formulated as MMX Modified Release Tablet vs. Rifaximin
Volume: 11 Issue: 2
Author(s): A.F.D. Di Stefano, D. Binelli, W. Labuschagne, M. Mojapelo, E. van der Walt, S. Patel and L. Moro
Affiliation:
Keywords: Infectious diarrhoea, MMX, non-absorbable antibiotics, rifamycin SV, rifaximin.
Abstract: Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.
Export Options
About this article
Cite this article as:
Stefano A.F.D. Di, Binelli D., Labuschagne W., Mojapelo M., Walt E. van der, Patel S. and Moro L., Efficacy of the Treatment of Infectious Diarrhoea with Non-Absorbable Rifamycin SV Formulated as MMX Modified Release Tablet vs. Rifaximin, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020013
DOI https://dx.doi.org/10.2174/2211352511311020013 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases
Reviews on Recent Clinical Trials Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry A Case of Postpartum Maternal Death with COVID-19 in the West of Iran
Current Women`s Health Reviews Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Evaluation of the Fibromyalgia and Related Risk Factors in Patients with Advanced Kidney Failure Undergoing Hemodialysis
Current Rheumatology Reviews p38 MAPK: A Potential Target of Chronic Pain
Current Medicinal Chemistry Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Therapeutic Strategies in Allergic Contact Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Role of Androgens in Womens Sexual Function & Dysfunction: What Have We Learned in Six Decades?
Current Women`s Health Reviews Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Efficacy of Fluoroquinolones Against Pathogenic Oral Bacteria
Mini-Reviews in Medicinal Chemistry JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Anti-Cancer Agents in Medicinal Chemistry Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Pasireotide - Mechanism of Action and Clinical Applications
Current Drug Metabolism Patent Selections
Recent Patents on Cardiovascular Drug Discovery